Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules
Patent Number: 8,173,611
Filed: Nov. 14, 2005
Lead Inventor: David Brown, Asuragen
The invention, the patent's abstract states, “concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the ... invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.”
Title: Therapeutic Compositions Comprising an RNAi Agent and a Neurotrophic Factor and Methods of Use Thereof
Patent Number: 8,173,614
Filed: Oct. 16, 2009
Lead Inventor: Eric Neal Burright, Medtronic
“The invention provides novel combination therapies for treating Huntington's disease which comprise [brain-derived neurotrophic factor] or suitable fragments thereof and agents capable of causing inhibition of a gene responsible for the neurodegenerative disease,” the patent's abstract states. “The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies.”
Title: RNAi-Induced Translational Silencing and Cellular Apoptosis
Patent Number: 8,173,616
Filed: Oct. 29, 2010
Lead Inventor: Paul Anderson, Brigham and Women's Hospital
“The invention is directed to RNA molecules that can be used to inhibit protein synthesis and to induce cells to undergo apoptosis,” according to the patent's abstract. “It also includes pharmaceutical compositions containing the RNAs that can be used in treating or preventing tumors, abnormal dermatological growths, and viral infections.”
Title: RNAi-Mediated Inhibition of Frizzled-Related Protein-1 for Treatment of Glaucoma
Patent Number: 8,173,617
Filed: April 12, 2011
Lead Inventor: Abbot Clark, Novartis
“RNA interference is provided for inhibition of frizzled-related protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma,” the patent's abstract states.
Title: Synthetic Methods and Derivatives of Triphosphate Oligonucleotides
Application Number: 20120107272
Filed: Sept. 2, 2009
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
“The invention features a oligonucleotide of [a pre-defined] formula ... or pharmaceutically acceptable salts, or pro-drugs thereof … [that] are capable of inducing an antiviral or an antibacterial response, in particular, the induction of type I IFN, IL-18, and/or IL-1-beta- by binding to RIG-I,” the patent application's abstract states. “The invention relates to methods of making and using modified oligonucleotide comprising at least one triphosphate or analogs thereof. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies, and immunosuppression.”
Title: Double-Stranded Oligonucleotides
Application Number: 20120107897
Filed: Aug. 16, 2011
Inventor: Tod Woolf, Life Technologies
The invention, the patent application's abstracts states, comprises “antisense sequences, including duplex RNAi compositions, [that] possess improved properties over those taught in the prior art. ... The invention provides optimized antisense oligomer compositions and methods for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.”
Title: RNAi Modulation of TGF-Beta and Therapeutic Uses Thereof
Application Number: 20120108646
Filed: Oct. 29, 2010
Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals
The invention, the patent application's abstract states, “concerns methods of treatment using transforming growth factor-beta modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.”
Title: Therapeutic Uses of Inhibitors of RTP-801L
Application Number: 20120108647
Filed: Aug. 25, 2011
Inventor: Elena Feinstein, Quark Pharmaceuticals
The invention, the patent application's abstract states, “provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases, respiratory conditions, and hearing disorders based upon inhibition of the RTP801L gene and/or protein.”
Title: microRNA Markers and Methods Related Thereto
Application Number: 20120108650
Filed: Oct. 28, 2011
Lead Inventor: Peng Jin, Emory University
The invention comprises “methods of diagnosis of Alzheimer's disease, including assessing the levels of certain microRNAs in a subject and comparing these to levels in subjects not exhibiting the disease,” the patent application's abstract states. “The identified measurements provide input for improved diagnoses of Alzheimer's disease as compared to certain other forms of dementias, which allows more effective treatment regimens.”
Title: Methods of Diagnosing and Treating Carcinomas
Application Number: 20120108655
Filed: March 5, 2010
Lead Inventor: Michele Avissar, Brown University
The patent application, its abstract states, claims “methods of diagnosing a carcinoma, [including] comparing the expression of miRNAs in a sample with a control and determining ratios of expression of miRNAs. Methods of treatment include administering a nucleic acid encoding a miR-375 gene product. Methods of optimizing treatment in a subject include determining expression of an miR21-gene product.”
Title: Use of microRNA-199b-5p in Medical and Diagnostic Field
Application Number: 20120108656
Filed: March 23, 2010
Inventor: Massimo Zollo, University of Naples Federico II
“This invention concerns the use of microRNA-199b-5p in medical and diagnostic fields,” the patent application's abstract states. “Particularly, this invention concerns the use of the miR-199b-5p in the anti-cancer therapy and as a histopathological and metastasis marker.”
Title: siRNA Conjugate and Preparation Method Thereof
Application Number: 20120108803
Filed: May 13, 2010
Lead Inventor: Bo Ram Han, Bioneer
The patent application, its abstract states, claims “an siRNA-polymer conjugate and a method for preparing the same ... to a hybrid conjugate formed by covalently bonding siRNA and a polymeric compound for improving the in vivo stability of siRNA, and to a preparation method of the hybrid conjugate. The conjugate of the ... invention can improve the in vivo stability of siRNA, thereby achieving an efficient delivery of therapeutic siRNA into cells and exhibiting the activity of siRNA even with a small dose of a relative low concentration. Therefore, the conjugate can advantageously be used as not only an siRNA treatment tool for cancers and other infectious disease, but also a novel type siRNA delivery system.”
Title: Compositions and Methods for Preparing Short RNA Molecules and Other Nucleic Acids
Application Number: 20120108804
Filed: July 25, 2011
Lead Inventor: Knut Madden, Life Technologies
“The invention provides methods of preparing nucleic acids, such as RNA molecules, of a defined size or range of sizes,” the patent application's abstract states. “The invention provides compositions, methods, and kits for use in the production and preparation of small RNA molecules ... and other nucleic acids of various sizes.”